Platform enables precise, efficient delivery of genetic medicines in vivo
Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform. Read More
Manufacturing remains big challenge for cell and gene therapy industry
Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry. Read More
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders. Read More
Panel to focus on pluripotent stem cells at Cell & Gene Meeting on the Mesa
A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies. Read More
6 startups to compete for $250K grand prize at 2022 BioTools Innovator capstone event
BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa. Read More
Meeting on the Mesa comes at pivotal time for cell and gene therapy industry
Stakeholders from around the cell and gene therapy sector will come together during the Alliance for Regenerative Medicine’s hybrid 2022 Meeting on the Mesa, October 11-13 in Carlsbad, CA, to discuss the opportunities and challenges facing the industry. Read More
Akadeum looks to advance the cell separation process with microbubbles
Microbubble technology offers researchers the ability to perform cell separation without a column or magnet, generating higher yield and faster turnaround times, according to Akadeum Life Sciences CEO Brandon McNaughton who spoke with ScienceBoard.net about the company's technology. Read More
Video from AACC: Fluxergy's multimodal testing platform
Fluxergy president and co-founder Tej Patel sat down with us at AACC 2022 and discussed the company’s multimodal, multiomic platform that enables doctors to perform different kinds of tests, including reverse transcription polymerase chain reaction and serology tests, using a single instrument and software program. Read More
Video from AACC: First impressions, Day 1
Reflecting on highlights from the LabPulse.com and ScienceBoard.net team for Day 1, Kalorama Information's Bruce Carlson compares AACC 2022 with previous meetings. Read More
Video from AACC: PerkinElmer on diagnostics, acquisitions
Greg Stock, general manager of PerkinElmer’s Euroimmun business, discussed products and technologies on display at AACC 2022, as well as the integration of acquired companies such as Oxford Immunotec. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter